Evidence map›Paper›PMID 35460295›Full record

Trial reportScandinavian journal of medicine & science in sports2022

Beta

Morten Hostrup, Jakob Grunnet Knudsen, Caroline Maag Kristensen, Søren Jessen, Henriette Pilegaard, Jens Bangsbo

Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Scandinavian journal of medicine & science in sports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. BetaScandinavian journal of medicine & science in sports · 2022
    Trial
  2. Efficacy and safety of salbutamol in treatment of children with later-onset spinal muscular atrophy.Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2023
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Morten HostrupAugust Krogh Section of Human Physiology, Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark.ORCID https://orcid.org/0000-0002-6201-2483
Jakob Grunnet KnudsenSection for Cell Biology and Physiology, Department of Biology, University of Copenhagen, Copenhagen, Denmark.
Caroline Maag KristensenSection for Cell Biology and Physiology, Department of Biology, University of Copenhagen, Copenhagen, Denmark.
Søren JessenAugust Krogh Section of Human Physiology, Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark.ORCID https://orcid.org/0000-0002-7461-1264
Henriette PilegaardSection for Cell Biology and Physiology, Department of Biology, University of Copenhagen, Copenhagen, Denmark.ORCID https://orcid.org/0000-0002-1071-0327
Jens BangsboAugust Krogh Section of Human Physiology, Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark.ORCID https://orcid.org/0000-0003-1305-9274
University of Copenhagen · DK

Funding

Kulturministeriet
6 · The paper itself

Abstract

objectiveSeveral tissues produce and release interleukin-6 (IL-6) in response to beta

designThe study employed a randomized controlled crossover design, where 12 men ingested either salbutamol (16 mg) or placebo for 4 days, followed by the last dose (24 mg) administered 1½ h before exercise. Arterial and femoral venous plasma IL-6 as well as femoral artery blood flow was measured before and ½-5 h in recovery from quadriceps muscle resistance exercise. Furthermore, vastus lateralis muscle biopsies were collected ½ and 5 h after exercise for determination of mRNA levels of IL-6 and Tumor Necrosis Factor (TNF)-α.

resultsAverage leg IL-6 release was 1.7-fold higher (p = 0.01) for salbutamol than placebo, being 138 ± 76 and 79 ± 66 pg min

conclusionsBeta

Indexed as

Interleukin-6Resistance TrainingAdrenergic AgentsAdrenergic beta-2 Receptor AgonistsAlbuterolHumansMaleMuscle, SkeletalRNA, MessengerTumor Necrosis Factor-alphaAdrenergic AgentsAdrenergic beta-2 Receptor AgonistsAlbuterolInterleukin-6RNA, MessengerTumor Necrosis Factor-alphabeta2beta2-adrenoceptorbeta-adrenoceptorcytokineSABA

Identifiers

PMID35460295
PMCPMC9545867
OpenAlexW4224311362

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.